Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 28Neoplasm Metastasis 3Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumours 1Small Cell Lung Carcinoma 1Prostatic Neoplasms, Castration-Resistant 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Small Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Sunitinib 2Paclitaxel 2valrubicin 1temsirolimus 1sipuleucel-T 1luprolide acetate gel depot 1ferumoxtran-10 1abiraterone 1abemaciclib 1Suspensions 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy 1Prednisone 1Prednisolone 1Powders 1Pemetrexed 1Neoadjuvant Therapy 1National Cancer Institute (U.S.) 1Mitomycin 1Magnetic Resonance Spectroscopy 1Leuprolide 1Fatty Acids, Omega-3 1Educational Status 1Docetaxel 1Bevacizumab 1Atorvastatin 1Administration, Intravesical 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urogenital Neoplasms × abiraterone × Clear all
NCT05288166 2025-06-27

CYCLONE 3

Eli Lilly and Company

Phase 3 Active not recruiting
925 enrolled 12 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡